Archimedes Cancer Pain Drug Approved in EU

Archimedes Pharma Ltd. was granted marketing authorization from the European Commission for its lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid thera

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Archimedes Pharma Ltd. was granted marketing authorization from the European Commission for its lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. BTCP is sudden, unpredictable episodes of pain that are severe to excruciating in intensity. BTCP affects 24% to 95% of all cancer patients despite background pain medication. PecFent contains fentanyl, a highly p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters